Back to search
Recurrent Astrocytoma, IDH-Mutant, Grade 4
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Astrocytoma, IDH-Mutant, Grade 4 trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Astrocytoma, IDH-Mutant, Grade 4 trials you may qualify forThis phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube…
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype gliobl…
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblast…
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial…
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and car…
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or ast…